Literature DB >> 29452230

A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia.

Haiying Li1, Chongyun Xing2, Bin Zhou1, Haige Ye2, Jianhua Feng2, Jianbo Wu1, Shenmeng Gao3.   

Abstract

The aberrant overexpression of Wilms tumor-1 (WT1) in acute myeloid leukemia (AML) plays an important role in blast cell survival by enhancing proliferation and inhibiting apoptosis. However, the mechanism underlying the overexpression of WT1 remains unclear. Here, we identified miR-193a (miR-193a-5p) and miR-600 targeting and degrading WT1. MiR-193a and miR-600 synergistically reduced WT1 expression and suppressed the activity of a luciferase reporter by binding coding sequence and the 3'-untranslated region of WT1 mRNA, respectively. Furthermore, the expression of miR-193a and miR-600 was decreased in AML patients compared with normal controls. DNA hypermethylation in pre-miR-193a promoter, but not pre-miR-600 promoter, caused the downregulation of miR-193a. Most intriguingly, ectopic expression of WT1 inhibited miR-600 expression, in turn, by binding the putative pre-miR-600 promoter, leading to the downregulation of miR-600 in AML blasts. Ectopic expression of miR-193a and miR-600 synergistically inhibited cell proliferation, induced apoptosis, and decreased colony formation in leukemia cells. Finally, overexpression of miR-193a and miR-600 decreased the growth of K562-inoculated tumor xenografts and extended survival time in THP1-transplanted leukemia mice. In conclusion, these data reveal an important role of miRNAs-WT1 circuitry in leukemia cells and the therapeutic promise of restoring miR-193a and miR-600 expression in AML patients.
Copyright © 2018 ISEH – Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29452230     DOI: 10.1016/j.exphem.2018.02.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.

Authors:  Bin Zhou; Xianghong Jin; Weiwei Jin; Xingzhou Huang; Yanfei Wu; Haiying Li; Weijian Zhu; Xiaoyi Qin; Haige Ye; Shenmeng Gao
Journal:  J Transl Med       Date:  2020-06-24       Impact factor: 5.531

Review 2.  Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.

Authors:  Svetlana Miroshnichenko; Olga Patutina
Journal:  Front Pharmacol       Date:  2019-05-16       Impact factor: 5.988

3.  miR-600 inhibits lung cancer via downregulating the expression of METTL3.

Authors:  Wenwen Wei; Baosheng Huo; Xiulan Shi
Journal:  Cancer Manag Res       Date:  2019-02-01       Impact factor: 3.989

4.  Targeting miR-193a-AML1-ETO-β-catenin axis by melatonin suppresses the self-renewal of leukaemia stem cells in leukaemia with t (8;21) translocation.

Authors:  Bin Zhou; Haige Ye; Chongyun Xing; Bin Liang; Haiying Li; Linling Chen; Xingzhou Huang; Yanfei Wu; Shenmeng Gao
Journal:  J Cell Mol Med       Date:  2019-05-22       Impact factor: 5.310

5.  LncRNA TUG1 Regulates Cell Viability and Death by Regulating miR-193a-5p/Rab10 Axis in Acute Myeloid Leukemia.

Authors:  Qun Li; Jianmin Wang
Journal:  Onco Targets Ther       Date:  2020-02-13       Impact factor: 4.147

6.  Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma.

Authors:  Jiajia Li; Haiying Li; Weijian Zhu; Bin Zhou; Jianchao Ying; Jiansheng Wu; Huxiang Zhang; Hongwei Sun; Shenmeng Gao
Journal:  J Cell Mol Med       Date:  2019-12-17       Impact factor: 5.310

7.  LncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and epithelial-mesenchymal transition in colorectal cancer.

Authors:  Junfeng Sun; Jiyi Hu; Guojun Wang; Zhen Yang; Chunlin Zhao; Xiefu Zhang; Jiaxiang Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-05-18

Review 8.  Abnormal microRNA expression in the course of hematological malignancies.

Authors:  Agnieszka Szymczyk; Arkadiusz Macheta; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.